Josep V Forment
Overview
Explore the profile of Josep V Forment including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1624
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sandy Z, Wang Z, Behera D, Foster B, Martin F, Bruninghoff K, et al.
PLoS One
. 2025 Jan;
20(1):e0316321.
PMID: 39869599
Non-covalent protein-protein interactions are one of the most fundamental building blocks in cellular signalling pathways. Despite this, they have been historically hard to identify using conventional methods due to their...
2.
Coelho M, Strauss M, Watterson A, Cooper S, Bhosle S, Illuzzi G, et al.
Nat Genet
. 2024 Oct;
56(11):2479-2492.
PMID: 39424923
Drug resistance is a principal limitation to the long-term efficacy of cancer therapies. Cancer genome sequencing can retrospectively delineate the genetic basis of drug resistance, but this requires large numbers...
3.
Herencia-Ropero A, Llop-Guevara A, Staniszewska A, Domenech-Vivo J, Garcia-Galea E, Moles-Fernandez A, et al.
Genome Med
. 2024 Aug;
16(1):107.
PMID: 39187844
Background: Poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitors (PARPi) are targeted therapies approved for homologous recombination repair (HRR)-deficient breast, ovarian, pancreatic, and prostate cancers. Since inhibition of PARP1 is...
4.
Davies N, Francis T, Oldreive C, Azam M, Wilson J, Byrd P, et al.
Haematologica
. 2024 Jun;
109(12):3989-4006.
PMID: 38841800
Diffuse large B-cell lymphoma (DLBCL) is the most common malignancy that develops in patients with ataxia-telangiectasia, a cancer-predisposing inherited syndrome characterized by inactivating germline ATM mutations. ATM is also frequently...
5.
Dibitetto D, Liptay M, Vivalda F, Dogan H, Gogola E, Gonzalez Fernandez M, et al.
Nat Commun
. 2024 May;
15(1):4430.
PMID: 38789420
Histone H2AX plays a key role in DNA damage signalling in the surrounding regions of DNA double-strand breaks (DSBs). In response to DNA damage, H2AX becomes phosphorylated on serine residue...
6.
Sharma A, Ramlee M, Kosmin J, Higgs M, Wolstenholme A, Ronson G, et al.
Nat Commun
. 2023 Nov;
14(1):7784.
PMID: 38012134
No abstract available.
7.
OConnor M, Forment J
Cancer Treat Res
. 2023 Nov;
186:25-42.
PMID: 37978129
Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) represent the first medicines based on the targeting of the DNA damage response (DDR). PARPi have become standard of care for first-line maintenance treatment in...
8.
Sharma A, Ramlee M, Kosmin J, Higgs M, Wolstenholme A, Ronson G, et al.
Nat Commun
. 2023 Aug;
14(1):5003.
PMID: 37591890
While the toxicity of PARP inhibitors to cells with defects in homologous recombination (HR) is well established, other synthetic lethal interactions with PARP1/PARP2 disruption are poorly defined. To inform on...
9.
Wimberger S, Akrap N, Firth M, Brengdahl J, Engberg S, Schwinn M, et al.
Nat Commun
. 2023 Aug;
14(1):4761.
PMID: 37580318
Genome editing, specifically CRISPR/Cas9 technology, has revolutionized biomedical research and offers potential cures for genetic diseases. Despite rapid progress, low efficiency of targeted DNA integration and generation of unintended mutations...
10.
Zelceski A, Francica P, Lingg L, Mutlu M, Stok C, Liptay M, et al.
Cell Rep
. 2023 May;
42(5):112484.
PMID: 37163373
The PSMC3IP-MND1 heterodimer promotes meiotic D loop formation before DNA strand exchange. In genome-scale CRISPR-Cas9 mutagenesis and interference screens in mitotic cells, depletion of PSMC3IP or MND1 causes sensitivity to...